Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press29110.17650/1994-4098-2009-0-1-2-53-58PHARMACOTHERAPYГИНЕКОЛОГИЯ. ФАРМАКОТЕРАПИЯIMPROVEMENT OF OVERALL SURVIVAL WITH PRIMARY BREAST CANCER WITH MICROMESTASES TO THE BONE MARROW BY ADJUVANT CLODRONATE THERAPYУЛУЧШЕНИЕ ОБЩЕЙ ВЫЖИВАЕМОСТИ БОЛЬНЫХ ПЕРВИЧНЫМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ С МИКРОМЕТАСТАЗАМИ В КОСТНЫЙ МОЗГ БЛАГОДАРЯ ПРИМЕНЕНИЮ КЛОДРОНАТА В АДЪЮВАНТНОМ РЕЖИМЕDielI.J.ДиельИ. Ж.
Germany
JaschkeA.ДжашкеА.
Germany
SolomayerE. F.СоломайерЕ. Ф.
Germany
GolanS.ГоланС.
Germany
BastertG.БастертГ.
Germany
SohnS.СонС.
Germany
SchuetzF.ШуетцФ.
Germany
Department of Obstetrics and Gynecology, University of Heidelberg Institute of Oncogynecology, MannheimОтделение акушерства и гинекологии Университета Гейдельберга Институт онкогинекологии, МанхеймDepartment of Obstetrics and Gynecology, University of HeidelbergОтделение акушерства и гинекологии Университета ГейдельбергаDepartment of Obstetrics and Gynecology, University of TuebingenОтделение акушерства и гинекологии Университета Тубингена, Германия010520091-2535803092014030920142009https://ojrs.abvpress.ru/ojrs/article/view/291

Supplementation of oral clodronate to postoperative adjuvant treatment for breast cancer (BC) considerably improves overall and relapse-free survival rates. The paper gives the results of a long-term follow-up of patients during a prospective randomized controlled study.Subjects and methods. The study included patients with primary BC receiving clodronate in a dose of 1600 mg/day in combination with the conventional adjuvant therapy for BC.Results. An analysis of 290 of 302 patients indicated a significant increase in overall survival in the clodronate group at a median fol- low-up of 103±12 months; during 8.5 years after primary surgical treatment, 20.4% and 40.7% of patients died in the clodronate and control groups, respectively (p = 0.04). The clodronate group did not show a considerable reduction in the rate of metastatic lesions in the bone and visceral organs or an increase in the relapse-free period following 36- and 55-month follow-ups.Conclusions. The findings of better late overall survival rates confirm the results of earlier studies of oral clodronate in combination with the conventional adjuvant therapy for BC.

УЛУЧШЕНИЕ ОБЩЕЙ ВЫЖИВАЕМОСТИ БОЛЬНЫХ ПЕРВИЧНЫМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ С МИКРОМЕТАСТАЗАМИ В КОСТНЫЙ МОЗГ БЛАГОДАРЯ ПРИМЕНЕНИЮ КЛОДРОНАТА В АДЪЮВАНТНОМ РЕЖИМЕ

adjuvant therapybisphosphonatebreast tumorclodronate1. American Cancer Society. Breast can- cer facts and figures, 2003—2004. Atlanta, GA: American Cancer Society Inc., 2003.American Cancer Society. Breast can- cer facts and figures, 2003—2004. Atlanta, GA: American Cancer Society Inc., 2003.2. Ferlay J., Bray P., Pisani P., Parkin D.M. GLOBOCAN 2002: Cancer Incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Version 2.0. IARC Press 2004.Ferlay J., Bray P., Pisani P., Parkin D.M. GLOBOCAN 2002: Cancer Incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Version 2.0. IARC Press 2004.3. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61—6.Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61—6.4. McCloskey E.V., Guest J.F., Kanis J.A. The clinical and cost consid- erations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001;61:1253—74.McCloskey E.V., Guest J.F., Kanis J.A. The clinical and cost consid- erations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001;61:1253—74.5. Paterson A.H. The role of adjuvant therapy with bisphosphonates in cancer. Am J Cancer 2004;3:25—39.Paterson A.H. The role of adjuvant therapy with bisphosphonates in cancer. Am J Cancer 2004;3:25—39.6. Mundy G. Preclinical models of bone metastases. Semin Oncol 2001;28:2—8.Mundy G. Preclinical models of bone metastases. Semin Oncol 2001;28:2—8.7. Yoneda T., Michigami T., Yi B. et al. Actions of bisphosphonate on bone metastasis in animal models of breast car- cinoma. Cancer 2000;88:2979—88.Yoneda T., Michigami T., Yi B. et al. Actions of bisphosphonate on bone metastasis in animal models of breast car- cinoma. Cancer 2000;88:2979—88.8. Powles T.J., Paterson A.H.G., Kanis J.A. et al. Randomized, placebo- controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219—24.Powles T.J., Paterson A.H.G., Kanis J.A. et al. Randomized, placebo- controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219—24.9. Diel I.J., Solomayer E.F., Costa S.D. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357— 63.Diel I.J., Solomayer E.F., Costa S.D. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357— 63.10. Diel I.J. Bisphosphonates in the prevention of bone metastases: current evi- dence. Semin Oncol 2001;28:75—80.Diel I.J. Bisphosphonates in the prevention of bone metastases: current evi- dence. Semin Oncol 2001;28:75—80.11. Powles T.J., Paterson A.H.G., McCloskey E. et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13.Powles T.J., Paterson A.H.G., McCloskey E. et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13.12. Diel I.J., Kaufmann M., Goerner R. et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534—9.Diel I.J., Kaufmann M., Goerner R. et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534—9.13. Diel I.J., Kaufmann M., Costa S.D. et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prog- nostic value in comparison with nodal status. J Natl Cancer Inst 1996;88: 1652—8.Diel I.J., Kaufmann M., Costa S.D. et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prog- nostic value in comparison with nodal status. J Natl Cancer Inst 1996;88: 1652—8.14. Janni W., Rack B., Sommer H. et al. Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metas- tases. J Cancer Res Clin Oncol 2003;129:503—10.Janni W., Rack B., Sommer H. et al. Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metas- tases. J Cancer Res Clin Oncol 2003;129:503—10.15. American Cancer Society. Breast cancer facts and figures, 2005—2006. Atlanta, GA: American Cancer Society Inc., 2005.American Cancer Society. Breast cancer facts and figures, 2005—2006. Atlanta, GA: American Cancer Society Inc., 2005.16. Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clo- dronate treatment does not reduce the frequency of skeletal metastases in node- positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10—7.Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clo- dronate treatment does not reduce the frequency of skeletal metastases in node- positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10—7.17. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year fol- low-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650—6.Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year fol- low-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650—6.18. Mundy G.R. Realising the potential of anti-host cell therapy. Cancer Today 2004;(Suppl 1):6—8.Mundy G.R. Realising the potential of anti-host cell therapy. Cancer Today 2004;(Suppl 1):6—8.19. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584—93.Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584—93.20. Boissier S., Ferreras M., Peyruchaud O. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949—54.Boissier S., Ferreras M., Peyruchaud O. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949—54.21. Fromigue O., Lagneaux L., Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211—21.Fromigue O., Lagneaux L., Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211—21.22. Fromigue O., Kheddoumi N., Body J.J. Bisphosphonates antagonise bone growth factors’ effects on human breast cancer cells survival. Br J Cancer 2003;89:178—84.Fromigue O., Kheddoumi N., Body J.J. Bisphosphonates antagonise bone growth factors’ effects on human breast cancer cells survival. Br J Cancer 2003;89:178—84.23. Rack B.K., Janni W., Schindlbeck C. et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recur- rence of early breast cancer. Proc Am Soc Clin Oncol 2004;23:abstr 9515.Rack B.K., Janni W., Schindlbeck C. et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recur- rence of early breast cancer. Proc Am Soc Clin Oncol 2004;23:abstr 9515.24. Kanis J.A., Powles T.J., Paterson A.H.G. et al. Clodronate decreases the frequency of skeletal metas- tases in women with breast cancer. Bone 1996;19:663—7.Kanis J.A., Powles T.J., Paterson A.H.G. et al. Clodronate decreases the frequency of skeletal metas- tases in women with breast cancer. Bone 1996;19:663—7.